American Vanguard Opportunity From Zika Being Overestimated, Says Suntrust

SunTrust analyst James Sheehan attributes the 26% jump in shares of American Vanguard (AVD) over the last week to speculation that mosquitocide sales will surge in response to the Zika virus, but he believes the Zika opportunity is being overestimated. The analyst maintains his Neutral rating and $14 price target on American Vanguard shares.

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.